Skip to the main content.
Other Therapy Areas

Extending our scientific depth across allergy, dermatology, ophthalmology, respiratory, women's health, and more.

Learn More →

Regulatory Considerations for Biosimilars Development in the U.S.

The development of biosimilar products in the U.S. has progressed since the regulatory pathway was established as part of the Affordable Care Act. Since then, the number of active biosimilar development programs has risen steadily. The market for these products is projected to exceed 100 billion dollars by 2028. 

Listen to the full episode on Veristat’s Advancing Revolutionary Therapies Podcast to learn more about the analytical and clinical science of biosimilars and their regulatory pathway.

Learning Points

  • Biosimilars vs. Generics
  • Demonstrating biosimilarity to a reference product
  • Evaluating comparative data between a biosimilar and reference product
  • Differences between regular and interchangeable biosimilars
  • Key regulatory considerations for development of biosimilars in the U.S.
  • Financial considerations for biosimilar development

LISTEN TO PODCAST

 

Meet Veristat. Learn More. 

Biosimilar FDA Meeting Types

Biosimilar FDA Meeting Types

It is crucial for biosimilar developers to engage early and often with FDA to ensure the health authority is well-informed and supports your planned...

Read More
Preserving What Matters: How Institutional Knowledge Protects Value Through M&A

Preserving What Matters: How Institutional Knowledge Protects Value Through M&A

Mergers and acquisitions (M&As) are a defining feature of today’s biopharmaceutical landscape. As companies merge pipelines, teams, and strategies,...

Read More
Navigating Regulatory Challenges in Biologics: A Case Study in Overcoming Clinical Holds

Navigating Regulatory Challenges in Biologics: A Case Study in Overcoming Clinical Holds

Explore how Veristat guided a biotech firm through a clinical hold, ensuring smooth biologics development. Download our case study for vital insights.

Read More